Leukemia Research and Treatment

Copyright © 2015 A. Rodríguez-Lirio et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. M. Paganin and A. Ferrando, “Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia,” Blood Reviews, vol. 25, no. 2, pp. 83–90, 2011. View at Publisher · View at Google Scholar · View at Scopus
2. I. Aifantis, E. Raetz, and S. Buonamici, “Molecular pathogenesis of T-cell leukaemia and lymphoma,” Nature Reviews Immunology, vol. 8, no. 5, pp. 380–390, 2008. View at Publisher · View at Google Scholar · View at Scopus
3. C.-H. Pui and W. E. Evans, “Treatment of acute lymphoblastic leukemia,” The New England Journal of Medicine, vol. 354, no. 2, pp. 166–178, 2006. View at Publisher · View at Google Scholar · View at Scopus
4. J. H. Park, C. Sauter, and R. Brentjens, “Cellular therapies in acute lymphoblastic leukemia,” Hematology/Oncology Clinics of North America, vol. 25, no. 6, pp. 1281–1301, 2011. View at Publisher · View at Google Scholar · View at Scopus
5. D. B. Longley and P. G. Johnston, “Molecular mechanisms of drug resistance,” The Journal of Pathology, vol. 205, no. 2, pp. 275–292, 2005. View at Publisher · View at Google Scholar · View at Scopus
6. Y. Zhao, E. B. Butler, and M. Tan, “Targeting cellular metabolism to improve cancer therapeutics,” Cell Death and Disease, vol. 4, no. 3, article e532, 2013. View at Publisher · View at Google Scholar · View at Scopus
7. E. Coustan-Smith, A. Kitanaka, C.-H. Pui et al., “Clinical relevance of BCL-2 overexpression in childhood acute lymphoblastic leukemia,” Blood, vol. 87, no. 3, pp. 1140–1146, 1996. View at Google Scholar · View at Scopus
8. Y. Su, X. Zhang, and P. J. Sinko, “Exploitation of drug-induced Bcl-2 overexpression for restoring normal apoptosis function: a promising new approach to the treatment of multidrug resistant cancer,” Cancer Letters, vol. 253, no. 1, pp. 115–123, 2007. View at Publisher · View at Google Scholar · View at Scopus
9. D.-O. Moon, M.-O. Kim, Y. H. Choi, N. D. Kim, J.-H. Chang, and G.-Y. Kim, “Bcl-2 overexpression attenuates SP600125-induced apoptosis in human leukemia U937 cells,” Cancer Letters, vol. 264, no. 2, pp. 316–325, 2008. View at Publisher · View at Google Scholar · View at Scopus
10. C.-Y. Jin, C. Park, J.-H. Lee et al., “Naringenin-induced apoptosis is attenuated by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human leukemia U937 cells,” Toxicology in Vitro, vol. 23, no. 2, pp. 259–265, 2009. View at Publisher · View at Google Scholar · View at Scopus
11. C.-Z. Kong and Z. Zhang, “Bcl-2 overexpression inhibits generation of intracellular reactive oxygen species and blocks adriamycin-induced apoptosis in bladder cancer cells,” Asian Pacific Journal of Cancer Prevention, vol. 14, no. 2, pp. 895–901, 2013. View at Publisher · View at Google Scholar · View at Scopus
12. R. G. Jones and C. B. Thompson, “Tumor suppressors and cell metabolism: a recipe for cancer growth,” Genes & Development, vol. 23, no. 5, pp. 537–548, 2009. View at Publisher · View at Google Scholar · View at Scopus
13. M. G. Vander Heiden, “Targeting cancer metabolism: a therapeutic window opens,” Nature Reviews Drug Discovery, vol. 10, no. 9, pp. 671–684, 2011. View at Publisher · View at Google Scholar · View at Scopus
14. R. A. Cairns, I. S. Harris, and T. W. Mak, “Regulation of cancer cell metabolism,” Nature Reviews Cancer, vol. 11, no. 2, pp. 85–95, 2011. View at Publisher · View at Google Scholar · View at Scopus
15. M. G. V. Heiden, “Exploiting tumor metabolism: challenges for clinical translation,” The Journal of Clinical Investigation, vol. 123, no. 9, pp. 3648–3651, 2013. View at Publisher · View at Google Scholar · View at Scopus
16. C. Rosilio, I. Ben-Sahra, F. Bost, and J.-F. Peyron, “Metformin: a metabolic disruptor and anti-diabetic drug to target human leukemia,” Cancer Letters, vol. 346, no. 2, pp. 188–196, 2014. View at Publisher · View at Google Scholar · View at Scopus
17. B. Viollet, B. Guigas, N. Sanz Garcia, J. Leclerc, M. Foretz, and F. Andreelli, “Cellular and molecular mechanisms of metformin: an overview,” Clinical Science, vol. 122, no. 6, pp. 253–270, 2012. View at Publisher · View at Google Scholar · View at Scopus
18. Y. Zhuang and W. K. Keith, “Cell cycle arrest in metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires ${\text{p2}\text{7}}^{\text{Kip1}}$ or ${\text{p21}}^{\text{Cip1}}$,” Journal of Molecular Signaling, vol. 3, article 18, 2008. View at Publisher · View at Google Scholar · View at Scopus
19. K. Kisfalvi, G. Eibl, J. Sinnett-Smith, and E. Rozengurt, “Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth,” Cancer Research, vol. 69, no. 16, pp. 6539–6545, 2009. View at Publisher · View at Google Scholar · View at Scopus
20. T. Tomic, T. Botton, M. Cerezo et al., “Metformin inhibits melanoma development through autophagy and apoptosis mechanisms,” Cell Death & Disease, vol. 2, article e199, 2011. View at Publisher · View at Google Scholar · View at Scopus
21. X. Xiao, Q. He, C. Lu et al., “Metformin impairs the growth of liver kinase B1-intact cervical cancer cells,” Gynecologic Oncology, vol. 127, no. 1, pp. 249–255, 2012. View at Publisher · View at Google Scholar · View at Scopus
22. R. J. O. Dowling, P. J. Goodwin, and V. Stambolic, “Understanding the benefit of metformin use in cancer treatment,” BMC Medicine, vol. 9, article 33, 2011. View at Publisher · View at Google Scholar · View at Scopus
23. M. N. Pollak, “Investigating metformin for cancer prevention and treatment: the end of the beginning,” Cancer Discovery, vol. 2, no. 9, pp. 778–790, 2012. View at Publisher · View at Google Scholar · View at Scopus
24. M. M. Mihaylova and R. J. Shaw, “The AMPK signalling pathway coordinates cell growth, autophagy and metabolism,” Nature Cell Biology, vol. 13, no. 9, pp. 1016–1023, 2011. View at Publisher · View at Google Scholar · View at Scopus
25. D. B. Shackelford and R. J. Shaw, “The LKB1-AMPK pathway: metabolism and growth control in tumour suppression,” Nature Reviews Cancer, vol. 9, no. 8, pp. 563–575, 2009. View at Publisher · View at Google Scholar · View at Scopus
26. J. U. Kazi, N. N. Kabir, and L. Rönnstrand, “Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia,” Medical Oncology, vol. 30, no. 4, article 757, 2013. View at Publisher · View at Google Scholar
27. R. Acin-Perez, B. Hoyos, J. Gong et al., “Regulation of intermediary metabolism by the PKC$\delta$ signalosome in mitochondria,” The FASEB Journal, vol. 24, no. 12, pp. 5033–5042, 2010. View at Publisher · View at Google Scholar · View at Scopus
28. M. Mayr, D. Liem, J. Zhang et al., “Proteomic and metabolomic analysis of cardioprotection: interplay between protein kinase C epsilon and delta in regulating glucose metabolism of murine hearts,” Journal of Molecular and Cellular Cardiology, vol. 46, no. 2, pp. 268–277, 2009. View at Publisher · View at Google Scholar · View at Scopus
29. J. Gong, B. Hoyos, R. Acin-Perez et al., “Two protein kinase C isoforms, δ and ε, regulate energy homeostasis in mitochondria by transmitting opposing signals to the pyruvate dehydrogenase complex,” The FASEB Journal, vol. 26, no. 8, pp. 3537–3549, 2012. View at Publisher · View at Google Scholar · View at Scopus
30. B. L. Hartmann, S. Geley, M. Löffler et al., “Bcl-2 interferes with the execution phase, but not upstream events, in glucocorticoid-induced leukemia apoptosis,” Oncogene, vol. 18, no. 3, pp. 713–719, 1999. View at Publisher · View at Google Scholar · View at Scopus
31. M.-C. Morales, G. Pérez-Yarza, N. Rementería et al., “4-HPR-mediated leukemia cell cytotoxicity is triggered by ceramide-induced mitochondrial oxidative stress and is regulated downstream by Bcl-2,” Free Radical Research, vol. 41, no. 5, pp. 591–601, 2007. View at Publisher · View at Google Scholar · View at Scopus
32. A. Apraiz, J. K. Idkowiak-Baldys, M. D. Boyano, G. Pérez-Yarza, Y. A. Hannun, and A. Asumendi, “Evaluation of bioactive sphingolipids in 4-HPR-resistant leukemia cells,” BMC Cancer, vol. 11, article 477, 2011. View at Publisher · View at Google Scholar · View at Scopus
33. A. S. Green, N. Chapuis, T. T. Maciel et al., “The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation,” Blood, vol. 116, no. 20, pp. 4262–4273, 2010. View at Publisher · View at Google Scholar · View at Scopus
34. W.-Y. Shi, D. Xiao, L. Wang et al., “Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy,” Cell Death and Disease, vol. 3, no. 3, article e275, 2012. View at Publisher · View at Google Scholar · View at Scopus
35. M. Pollak, “Metformin and other biguanides in oncology: advancing the research agenda,” Cancer Prevention Research, vol. 3, no. 9, pp. 1060–1065, 2010. View at Publisher · View at Google Scholar · View at Scopus
36. P. Zhang, H. Li, X. Tan, L. Chen, and S. Wang, “Association of metformin use with cancer incidence and mortality: a meta-analysis,” Cancer Epidemiology, vol. 37, no. 3, pp. 207–218, 2013. View at Publisher · View at Google Scholar · View at Scopus
37. R. Rattan, S. Giri, L. C. Hartmann, and V. Shridhar, “Metformin attenuates ovarian cancer cell growth in an AMP-kinase dispensable manner,” Journal of Cellular and Molecular Medicine, vol. 15, no. 1, pp. 166–178, 2011. View at Publisher · View at Google Scholar · View at Scopus
38. M. M. Alonso, A. Asumendi, J. Villar et al., “New benzo(b)thiophenesulphonamide 1,1-dioxide derivatives induce a reactive oxygen species-mediated process of apoptosis in tumour cells,” Oncogene, vol. 22, no. 24, pp. 3759–3769, 2003. View at Publisher · View at Google Scholar · View at Scopus
39. I. Marschitz, I. Tinhofer, A. Hittmair, A. Egle, M. Kos, and R. Greil, “Analysis of Bcl-2 protein expression in chronic lymphocytic leukemia. A comparison of three semiquantitation techniques,” American Journal of Clinical Pathology, vol. 113, no. 2, pp. 219–229, 2000. View at Publisher · View at Google Scholar · View at Scopus
40. Y.-H. Kim, J.-W. Park, J.-Y. Lee, Y.-J. Surh, and T. K. Kwon, “Bcl-2 overexpression prevents daunorubicin-induced apoptosis through inhibition of XIAP and Akt degradation,” Biochemical Pharmacology, vol. 66, no. 9, pp. 1779–1786, 2003. View at Publisher · View at Google Scholar · View at Scopus
41. Y. Miura, Y. Nishimura, H. Katsuyama et al., “Involvement of IL-10 and Bcl-2 in resistance against an asbestos-induced apoptosis of T cells,” Apoptosis, vol. 11, no. 10, pp. 1825–1835, 2006. View at Publisher · View at Google Scholar · View at Scopus
42. C. Park, C.-Y. Jin, H. J. Kwon et al., “Induction of apoptosis by esculetin in human leukemia U937 cells: roles of Bcl-2 and extracellular-regulated kinase signaling,” Toxicology in Vitro, vol. 24, no. 2, pp. 486–494, 2010. View at Publisher · View at Google Scholar · View at Scopus
43. A. J. Smith, H. Dai, C. Correia et al., “Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells,” The Journal of Biological Chemistry, vol. 286, no. 20, pp. 17682–17692, 2011. View at Publisher · View at Google Scholar · View at Scopus
44. A. W. Roberts, J. F. Seymour, J. R. Brown et al., “Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease,” Journal of Clinical Oncology, vol. 30, no. 5, pp. 488–496, 2012. View at Publisher · View at Google Scholar · View at Scopus
45. M. Zakikhani, R. Dowling, I. G. Fantus, N. Sonenberg, and M. Pollak, “Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells,” Cancer Research, vol. 66, no. 21, pp. 10269–10273, 2006. View at Publisher · View at Google Scholar · View at Scopus
46. G. M. Leclerc, G. J. Leclerc, J. N. Kuznetsov, J. DeSalvo, and J. C. Barredo, “Metformin induces apoptosis through AMPK-dependent inhibition of UPR signaling in ALL lymphoblasts,” PLoS ONE, vol. 8, no. 8, Article ID e74420, 2013. View at Publisher · View at Google Scholar · View at Scopus
47. K. Janjetovic, L. Harhaji-Trajkovic, M. Misirkic-Marjanovic et al., “In vitro and in vivo anti-melanoma action of metformin,” European Journal of Pharmacology, vol. 668, no. 3, pp. 373–382, 2011. View at Publisher · View at Google Scholar · View at Scopus
48. I. B. Sahra, K. Laurent, S. Giuliano et al., “Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells,” Cancer Research, vol. 70, no. 6, pp. 2465–2475, 2010. View at Publisher · View at Google Scholar · View at Scopus
49. G. Z. Rocha, M. M. Dias, E. R. Ropelle et al., “Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth,” Clinical Cancer Research, vol. 17, no. 12, pp. 3993–4005, 2011. View at Publisher · View at Google Scholar · View at Scopus
50. A. Yasmeen, M.-C. Beauchamp, E. Piura, E. Segal, M. Pollak, and W. H. Gotlieb, “Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins,” Gynecologic Oncology, vol. 121, no. 3, pp. 492–498, 2011. View at Publisher · View at Google Scholar · View at Scopus
51. A. Isakovic, L. Harhaji, D. Stevanovic et al., “Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis,” Cellular and Molecular Life Sciences, vol. 64, no. 10, pp. 1290–1302, 2007. View at Publisher · View at Google Scholar · View at Scopus
52. L. A. Cantrell, C. Zhou, A. Mendivil, K. M. Malloy, P. A. Gehrig, and V. L. Bae-Jump, “Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy,” Gynecologic Oncology, vol. 116, no. 1, pp. 92–98, 2010. View at Publisher · View at Google Scholar · View at Scopus
53. C. Grimaldi, F. Chiarini, G. Tabellini et al., “AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications,” Leukemia, vol. 26, no. 1, pp. 91–100, 2012. View at Publisher · View at Google Scholar · View at Scopus
54. C. Rosilio, N. Lounnas, M. Nebout et al., “The metabolic perturbators metformin, phenformin and AICAR interfere with the growth and survival of murine PTEN-deficient T cell lymphomas and human T-ALL/T-LL cancer cells,” Cancer Letters, vol. 336, no. 1, pp. 114–126, 2013. View at Publisher · View at Google Scholar · View at Scopus
55. S. Scotland, E. Saland, N. Skuli et al., “Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells,” Leukemia, vol. 27, no. 11, pp. 2129–2138, 2013. View at Publisher · View at Google Scholar · View at Scopus
56. S. K. Niture, A. Gnatt, and A. K. Jaiswal, “Oncogene PKCε controls INrf2-Nrf2 interaction in normal and cancer cells through phosphorylation of INrf2,” Journal of Cell Science, vol. 126, part 24, pp. 5657–5669, 2013. View at Publisher · View at Google Scholar
57. A. Singh, V. Misra, R. K. Thimmulappa et al., “Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer,” PLoS Medicine, vol. 3, no. 10, article e420, 2006. View at Publisher · View at Google Scholar · View at Scopus
58. J. W. Kaspar, S. K. Niture, and A. K. Jaiswal, “Nrf2:INrf2 (Keap1) signaling in oxidative stress,” Free Radical Biology & Medicine, vol. 47, no. 9, pp. 1304–1309, 2009. View at Publisher · View at Google Scholar · View at Scopus
59. J. H. No, Y. B. Kim, and Y. S. Song, “Targeting nrf2 signaling to combat chemoresistance,” Journal of Cancer Prevention, vol. 19, no. 2, pp. 111–117, 2014. View at Publisher · View at Google Scholar
60. S. K. Niture, A. K. Jain, and A. K. Jaiswal, “Antioxidant-induced modification of INrf2 cysteine 151 and PKC-δ-mediated phosphorylation of Nrf2 serine 40 are both required for stabilization and nuclear translocation of Nrf2 and increased drug resistance,” Journal of Cell Science, vol. 122, no. 24, pp. 4452–4464, 2009. View at Publisher · View at Google Scholar · View at Scopus